Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7464020 | 0.86 | CYP2C19 (0.46) | ELANEF2CYP1A2CYP2C19LMNA | |
| SCHEMBL344718 | 0.86 | ALOX5 (0.50) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 | |
| SCHEMBL9360749 | 0.85 | CYP19A1 (0.53) | CYP19A1FOLH1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1028419 | 0.83 | ALPG (0.51) | MAPTL3MBTL1TDP1ALPGPTK2B | |
| SCHEMBL7908188 | 0.79 | HSD17B10 (0.53) | LMNAHIF1ASMN1; SMN2L3MBTL1GAA | |
| SCHEMBL8980294 | 0.79 | LMNA (0.55) | ELANELMNAHDAC6CTSGMAPT | |
| SCHEMBL7042929 | 0.78 | FABP4 (0.53) | LMNAFOLH1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL8728948 | 0.78 | SLC2A1 (0.59) | ELANEF2CYP1A2CYP2C19LMNA | |
| SCHEMBL29721165 | 0.78 | SLC2A1 (0.59) | ELANEF2CYP1A2CYP2C19LMNA | |
| SCHEMBL15953373 | 0.77 | FABP4 (0.52) | LMNAFOLH1MAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018195-B2 | Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating skin photoaging | AmDerma Pharmaceuticals, LLC (US) | 2015-04-28 | — | — | US | claimed |
| US-20130202580-A1 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis | AmDerma Pharmaceuticals, LLC (US) | 2013-08-08 | — | — | US | claimed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | claimed |
| EP-2056805-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | claimed |
| EP-2054051-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | Investread Europe, S.L. (ES) | 2009-05-06 | — | — | EP | claimed |
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | claimed |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | disclosed |
| US-9060966-B2 | Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-06-23 | — | — | US | disclosed |
| US-9018195-B2 | Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating skin photoaging | AmDerma Pharmaceuticals, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130202580-A1 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis | AmDerma Pharmaceuticals, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020033-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ARSA, CYP8B1, EBP | ELANE 3209/4885F2 3799/4885CYP1A2 310/4885 |
| US-20130202580-A1 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis | CYP8B1, DERA, KRT18 | ELANE 1347/4885F2 3004/4885CYP1A2 251/4885 |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | CYP11B1, CYP11B2, MYLK | ELANE 1397/4885F2 1665/4885CYP1A2 76/4885 |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | CYP8B1, DERA, KRT18 | ELANE 1347/4885F2 3004/4885CYP1A2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.